A health care worker takes a nasal swab sample to test for the coronavirus at the Abyssinian Baptist Church in Harlem, New York City on May 13. Photo: Angela Weiss/AFP via Getty Images

An at-home coronavirus collection kit made by health care startup Everlywell has received emergency authorization from the Food and Drug Administration, the agency announced Saturday.

Why it matters: This is the only kit that can be used with multiple coronavirus tests, although two other at-home swabs have received authorization from the FDA. The swabs collected at home will be sent to labs for diagnosis.

Details: Everlywell's kit, which allows people to collect a nasal sample for the virus, is authorized for use based on the results of a COVID-19 questionnaire administered by health care providers, the FDA said.

What they're saying: “The authorization of a COVID-19 at-home collection kit that can be used with multiple tests at multiple labs not only provides increased patient access to tests, but also protects others from potential exposure,” Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health, said.

Go deeper... FDA: Abbott coronavirus test may falsely tell patients they don't have the virus

Go deeper

Scoop: The Trump-Navarro mind meld on the FDA

Peter Navarro speaks during a briefing on the pandemic, March 27. Photo: Drew Angerer/Getty Images

Senior health officials in the Trump administration were taken aback last Monday when the president's trade adviser, Peter Navarro, accused them of being part of the "Deep State" during a meeting that was supposed to be about COVID-19 and the Strategic National Stockpile.

Why it matters: Five days after Navarro's private comments toward the FDA, the president echoed Navarro's sentiments with a pair of Saturday morning tweets and tagged Stephen Hahn, the head of the Food and Drug Administration.

Aug 23, 2020 - Health

Ex-FDA chief rebukes Trump over claim that "deep state" has slowed virus treatments

Former FDA commissioner Scott Gottlieb said Sunday that he rejects President Trump's claim that the "deep state" at the FDA is delaying coronavirus treatments and vaccines for political reasons, telling CBS News' "Face the Nation" on Sunday: "It is a foundational truth that what guides that agency is science."

Why it matters: Gottlieb served as FDA commissioner for two years under the Trump administration. He pushed back on claims from Trump and White House Chief of Staff Mark Meadows that the agency's bureaucrats don't understand the "urgency" of the moment, saying, "To say these products aren't moving at a historic pace I think is wrong."

Updated Aug 23, 2020 - Politics & Policy

FDA announces emergency authorization of plasma treatment for COVID-19

Photo: Anna Moneymaker-Pool/Getty Images

The FDA announced Sunday it will grant an emergency use authorization (EUA) of convalescent plasma as a treatment for the coronavirus, one day after President Trump accused the agency of slow-walking the development of vaccines and therapeutics to hurt him politically.

The state of play: The authorization for plasma, which is safe but not yet proven to work on COVID-19, had been on hold after federal health officials intervened with the FDA last week and argued that the current data on the effectiveness of the treatment was too weak, the New York Times reported.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!